Acutus medical announces submission of premarket approval application for acqblate force sensing ablation catheter & system

Carlsbad, calif., oct. 18, 2022 (globe newswire) -- acutus medical, inc. (“acutus” or the “company”) (nasdaq: afib), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced submission of pivotal clinical data from the acqforce flutter trial designed to gain marketing approval from the u.s. food & drug administration (fda) for the acqblate force sensing ablation catheter and system (acqblate force). catheter ablation procedures to treat right atrial flutter account for approximately 30% of ablations in the us and are expected to reach 200,000 by 20251.
AFIB Ratings Summary
AFIB Quant Ranking